SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Rigel Pharmaceuticals, Inc. (RIGL)
RIGL 30.34-3.9%9:30 AM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: mopgcw who wrote (502)10/3/2010 1:30:43 PM
From: Steve Lokness  Read Replies (1) of 566
 
that it has earned $25 million from AstraZeneca for the fulfillment of two major milestones

Thanks. 25 million into the bank and, ......... AstraZeneca is responsible for all development, regulatory filings, manufacturing and global commercialization activities in all licensed indications under the contract. ........

In my thinking Rigel should have a balance sheet of over 200 million. 187 at end of second qtr. and some millions left from the original payment from AZ and this new 25 million payment. Last qtr expenses were 22.5.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News